296 related articles for article (PubMed ID: 17473981)
1. A Phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy.
Clemons M; Dranitsaris G; Ooi W; Cole DE
Breast Cancer Res Treat; 2008 Mar; 108(1):79-85. PubMed ID: 17473981
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
Clemons MJ; Dranitsaris G; Ooi WS; Yogendran G; Sukovic T; Wong BY; Verma S; Pritchard KI; Trudeau M; Cole DE
J Clin Oncol; 2006 Oct; 24(30):4895-900. PubMed ID: 17001071
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonates for breast cancer.
Pavlakis N; Schmidt R; Stockler M
Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom.
De Cock E; Hutton J; Canney P; Body JJ; Barrett-Lee P; Neary MP; Lewis G
Clin Ther; 2005 Aug; 27(8):1295-310. PubMed ID: 16199254
[TBL] [Abstract][Full Text] [Related]
5. A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer.
Jacobs C; Kuchuk I; Bouganim N; Smith S; Mazzarello S; Vandermeer L; Dranitsaris G; Dent S; Gertler S; Verma S; Song X; Simos S; Cella D; Clemons M
Breast Cancer Res Treat; 2016 Jan; 155(1):77-84. PubMed ID: 26643085
[TBL] [Abstract][Full Text] [Related]
6. Use of bisphosphonates in metastatic breast cancer: single institution review at the Dr. H. Bliss Murphy Cancer Centre.
Murphy L; McCarthy J; McCrate F; Laing K; Powell E; Seal M; Edwards S
Support Care Cancer; 2013 Jun; 21(6):1557-60. PubMed ID: 23334521
[TBL] [Abstract][Full Text] [Related]
7. Bisphosphonates for breast cancer.
Pavlakis N; Stockler M
Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
[TBL] [Abstract][Full Text] [Related]
8. A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events.
Addison CL; Bouganim N; Hilton J; Vandermeer L; Dent S; Amir E; Hopkins S; Kuchuk I; Segal R; Song X; Gertler S; Mazzarello S; Dranitsaris G; Ooi D; Pond G; Clemons M
Breast Cancer Res Treat; 2014 Apr; 144(3):615-24. PubMed ID: 24638849
[TBL] [Abstract][Full Text] [Related]
9. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer.
Small EJ; Smith MR; Seaman JJ; Petrone S; Kowalski MO
J Clin Oncol; 2003 Dec; 21(23):4277-84. PubMed ID: 14581438
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy.
De Cock E; Hutton J; Canney P; Body JJ; Barrett-Lee P; Neary MP; Lewis G
Support Care Cancer; 2005 Dec; 13(12):975-86. PubMed ID: 15871033
[TBL] [Abstract][Full Text] [Related]
11. Ibandronate: its role in metastatic breast cancer.
Cameron D; Fallon M; Diel I
Oncologist; 2006; 11 Suppl 1():27-33. PubMed ID: 16971737
[TBL] [Abstract][Full Text] [Related]
12. Oral ibandronate in metastatic bone breast cancer: the Florence University experience and a review of the literature.
Meattini I; Bruni A; Scotti V; Livi L; De Luca Cardillo C; Galardi A; Cipressi S; Biti G
J Chemother; 2010 Feb; 22(1):58-62. PubMed ID: 20227995
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of ibandronate for the treatment of skeletal events in patients with metastatic breast cancer.
Heras P; Kritikos K; Hatzopoulos A; Georgopoulou AP
Eur J Cancer Care (Engl); 2009 Nov; 18(6):653-6. PubMed ID: 19552728
[TBL] [Abstract][Full Text] [Related]
14. Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study.
Glover D; Lipton A; Keller A; Miller AA; Browning S; Fram RJ; George S; Zelenakas K; Macerata RS; Seaman JJ
Cancer; 1994 Dec; 74(11):2949-55. PubMed ID: 7525038
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials.
Gordon DH
Clin Breast Cancer; 2005 Jun; 6(2):125-31. PubMed ID: 16001990
[TBL] [Abstract][Full Text] [Related]
16. Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases.
Cremers SC; Papapoulos SE; Gelderblom H; Seynaeve C; den Hartigh J; Vermeij P; van der Rijt CC; van Zuylen L
J Bone Miner Res; 2005 Sep; 20(9):1543-7. PubMed ID: 16059626
[TBL] [Abstract][Full Text] [Related]
17. Loading dose ibandronate versus standard oral ibandronate in patients with bone metastases from breast cancer.
Macpherson IR; Bray C; Hopkins C; Hannon RA; Lewsley LA; Ritchie DM; Canney P
Clin Breast Cancer; 2015 Apr; 15(2):117-27. PubMed ID: 25454689
[TBL] [Abstract][Full Text] [Related]
18. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases.
Lipton A; Steger GG; Figueroa J; Alvarado C; Solal-Celigny P; Body JJ; de Boer R; Berardi R; Gascon P; Tonkin KS; Coleman R; Paterson AH; Peterson MC; Fan M; Kinsey A; Jun S
J Clin Oncol; 2007 Oct; 25(28):4431-7. PubMed ID: 17785705
[TBL] [Abstract][Full Text] [Related]
19. Bisphosphonates for cancer patients: why, how, and when?
Body JJ; Mancini I
Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
[TBL] [Abstract][Full Text] [Related]
20. Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer.
Diel IJ; Body JJ; Lichinitser MR; Kreuser ED; Dornoff W; Gorbunova VA; Budde M; Bergström B;
Eur J Cancer; 2004 Jul; 40(11):1704-12. PubMed ID: 15251160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]